Fetal Sacrococcygeal Teratoma: Surveillance And Fetal Therapy

Fetal sacrococcygeal teratoma (SCT) is an uncommon tumour arising near the base of the spine and coccyx. It may be detected during the routine mid-pregnancy ultrasound, although some lesions become apparent earlier or enlarge quickly later in gestation. The tumour can be mainly cystic, mainly solid, or a mixture of both, with blood flow ranging from modest to extremely high. Learn more about Fetal Surgery For Spina Bifida Current Outcomes.

The major prenatal concern is not simply tumour size. A large, highly vascular SCT can draw substantial blood flow from the fetal circulation, placing strain on the heart. This may lead to cardiomegaly, fetal anaemia, fluid accumulation, hydrops fetalis and, in severe cases, maternal mirror syndrome. Careful assessment is therefore focused on physiology as well as anatomy.

Management is individualised. Some pregnancies need regular ultrasound and planned delivery at a tertiary perinatal centre, while others may be considered for fetal therapy. Decisions depend on gestational age, tumour growth, vascularity, fetal cardiac function, hydrops, maternal health and the expertise available at the treating centre.

For families in Australia, the diagnosis often means referral from a local sonographer or obstetrician to a state-based fetal medicine service. A couple living in regional Queensland, Western Australia or the Northern Territory may need several trips to Brisbane, Perth, Adelaide, Melbourne or Sydney. Public and private pathways differ, and travel, accommodation, work leave and support for other children can become part of the clinical discussion.

How The Tumour Is Identified

Ultrasound usually shows a mass at the fetal sacrum, extending outward from the pelvis. The examiner records its dimensions, internal appearance, relationship to the spine and pelvis, and the degree of blood flow on colour Doppler. A predominantly cystic lesion may behave differently from a solid, highly vascular mass, so a single measurement does not provide the full picture.

The scan also looks for associated findings, including enlarged cardiac chambers, abnormal venous Doppler studies, ascites, pleural or pericardial fluid, skin oedema and excess amniotic fluid. These signs can indicate that the fetal heart is struggling. Serial imaging is essential because an apparently stable tumour can change rapidly over a fortnight.

Magnetic resonance imaging may help define the internal pelvic component and its relationship to the bladder, bowel and spinal structures, particularly when planning delivery or neonatal surgery. It does not replace ultrasound, which remains the main tool for monitoring blood flow and fetal wellbeing.

A suspected SCT should be distinguished from conditions such as myelomeningocele, sacrococcygeal meningocele, neuroblastoma and other pelvic masses. Families may find it useful to review how diagnostic imaging differs from spina bifida outcomes in specialist fetal surgery discussions, because the terminology and treatment pathways are not interchangeable.

Building A Prenatal Surveillance Plan

The surveillance schedule is guided by the tumour’s growth rate and the fetus’s cardiovascular response. A small lesion without concerning Doppler or cardiac findings may be reviewed every two to four weeks initially. A fast-growing or highly vascular tumour may require weekly assessment, sometimes with additional review between formal appointments.

Each visit may include tumour measurements, Doppler assessment of the middle cerebral artery, umbilical artery and venous circulation, amniotic fluid measurement, fetal growth and an echocardiogram. The middle cerebral artery peak systolic velocity can support assessment for fetal anaemia, while cardiac function is judged through several ultrasound parameters rather than one isolated number.

Clinicians also monitor the pregnant patient. Rapid abdominal enlargement, breathlessness, headaches, rising blood pressure, swelling or feeling unusually unwell should be reported promptly. Maternal mirror syndrome is rare but serious: the mother develops symptoms that mirror fetal hydrops, and urgent delivery or intervention may be required.

Surveillance should include a written escalation plan. It may specify who to call after hours, where to present if contractions or fluid loss occur, and when transfer to a tertiary hospital is recommended. In Australia, this matters when a family is travelling from the bush or from an outer suburb and the nearest maternity unit does not provide fetal therapy or neonatal surgery.

Additional Testing And Family Counselling

Most SCTs are isolated structural findings, but a detailed anatomical survey is recommended. The team may discuss chromosomal testing according to the ultrasound findings, family preferences and gestational age. Cell-free DNA screening is a screening test rather than a diagnostic test; amniocentesis provides diagnostic information when it is clinically indicated and accepted by the family.

The choice of testing should be explained in plain language, including the chance of an uncertain result, procedure-related risks and whether the result would alter pregnancy or neonatal planning. Information on fetal karyotyping options can help frame the difference between screening and diagnostic testing, although it cannot predict how an individual tumour will behave.

Counselling also covers the likely neonatal course. After birth, the baby commonly needs imaging, stabilisation and surgical removal of the tumour, including the coccyx to reduce recurrence risk. Pathology determines whether the lesion is mature, immature or contains malignant elements. Long-term follow-up may involve oncology, surgery, urology, bowel specialists and developmental services.

A fetal diagnosis is emotionally demanding, particularly when scan reports use terms such as “high-output cardiac failure” or “hydrops”. Families should be offered a coordinated consultation with maternal-fetal medicine, paediatric surgery, neonatology, anaesthesia and, where relevant, genetics and palliative care. Access to a social worker or perinatal psychologist is part of good care rather than an optional extra.

Comparing Monitoring And Fetal Intervention

In utero treatment is considered when the tumour threatens the fetus before a safe gestational age for delivery. The clearest concern is severe cardiovascular compromise caused by a large vascular mass. Fetal hydrops, progressive cardiac dysfunction and rapid tumour expansion can prompt discussion of intervention, but each case requires a specialist review.

Possible procedures include open fetal surgery, ultrasound-guided radiofrequency ablation, laser ablation of tumour vessels and drainage of selected cystic components. The aim may be to reduce blood flow, control tumour expansion or improve the chance of continuing the pregnancy. These procedures are technically complex and available only in highly specialised centres.

Evidence for fetal intervention remains limited because SCT is rare and treatment approaches vary between centres. A procedure that is appropriate for one tumour may be unsuitable for another because of placental position, fetal anatomy, gestational age or the amount of tumour inside the pelvis. Families should receive a balanced discussion of expected benefit, uncertainty and the alternative of continued surveillance or delivery.

Planning Birth In An Australian Centre

Birth should be planned where maternal care, neonatal intensive care, paediatric surgery, anaesthesia, radiology and blood products are immediately available. The delivery mode depends on tumour size, position, vascularity and the risk of rupture or bleeding. A caesarean birth may be recommended for a large external mass, while smaller lesions may allow vaginal birth after a multidisciplinary review.

Timing is a careful compromise. Continuing the pregnancy supports fetal maturation, but waiting may increase the risk of hydrops or maternal illness. If the fetus becomes unstable, delivery and postnatal treatment may be safer than further prenatal observation. Antenatal corticosteroids and magnesium sulphate may be considered when preterm birth is likely, according to gestation and local protocol.

Australian families may be referred to a tertiary service such as the Royal Women’s Hospital in Melbourne, Westmead Hospital in Sydney, the Mater Mothers’ Hospital in Brisbane, King Edward Memorial Hospital in Perth or the Women’s and Children’s Hospital in Adelaide. The precise pathway depends on state services, clinician expertise and available neonatal surgical capacity, so early referral is valuable.

For patients using the public system, Medicare generally supports medically necessary hospital care, but travel and accommodation arrangements still need attention. Some states provide patient transport or accommodation assistance for rural residents, while private care may involve different referral and insurance arrangements. A named coordinator can help organise appointments, records and transfers instead of leaving families to manage the logistics themselves.

Preparing For Neonatal Surgery

At birth, the neonatal team assesses breathing, circulation, temperature, blood loss and the tumour’s attachment. A large external mass can make positioning and airway management difficult, so the delivery-room plan should specify how the baby will be handled and which team member leads stabilisation.

Surgery usually removes the tumour and the coccyx. The operation may involve reconstruction of the perineum and management of the bowel, bladder or pelvic nerves if the lesion extends internally. Some babies need staged procedures, prolonged wound care or support for feeding and bladder or bowel function.

Prognosis depends on the tumour’s size, solid-to-cystic composition, vascularity, presence of hydrops, gestational age at birth and pathology. Even when the tumour is benign, children require surveillance for recurrence and assessment of functional outcomes. Malignant or immature elements may require paediatric oncology input.

Parents should ask how the centre manages pain, feeding, wound care, continence and developmental follow-up. They can also request a clear explanation of warning signs after discharge, expected hospital stay and who to contact. A practical plan reduces uncertainty during an already intense transition from pregnancy to neonatal care.

Coordinating Specialist Care

The best results come from a fetal medicine team that communicates consistently across pregnancy, birth and the postnatal period. The core group usually includes maternal-fetal medicine, fetal cardiology, neonatology, paediatric surgery, anaesthesia, radiology, genetics and nursing coordination. Allied health professionals add support with housing, transport, mental health and finances.

Invasive fetal procedures require particular attention to bleeding and procedural safety. If the mother has a history suggesting platelet antibodies or the fetus may be at risk of thrombocytopenia, the team may adapt testing and preparation. Specialist platelet management guidance is relevant when fetal procedures or neonatal bleeding risks overlap with suspected alloimmune thrombocytopenia, even though it is not a treatment for SCT itself.

Families should receive one agreed summary of scan findings, growth trends, cardiac status, intervention discussions and the birth plan. For people who say they are “doing it tough” with repeated travel or long hospital stays, practical support is clinically important. Telehealth can reduce some appointments, but it cannot replace in-person imaging or multidisciplinary review when the condition is changing.

Early referral to a fetal medicine unit gives the team time to confirm the diagnosis, monitor the pregnancy and discuss every reasonable pathway. Contact a specialist service promptly after an abnormal scan so that surveillance, travel support and neonatal planning can begin before the situation becomes urgent.